Takeda Submits a New Drug Application for Rasagiline Mesylate for the Treatment of Parkinson’s Disease in Japan

By Drugs, Pharmaceutical

Takeda Submits a New Drug Application for Rasagiline Mesylate for the Treatment of Parkinson’s Disease in Japan   −   Osaka, Japan, June 29, 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for rasagiline mesylate (generic name, development code: TVP-1012) for the treatment of Parkinson’s disease.

https://www.takeda.com/newsroom/newsreleases/2017/takeda-submits-a-new-drug-application-for-rasagiline-mesylate–for-the-treatment-of-parkinsons-disease-in-japan/

More from tokioX :

  1. South Korea, Ildong Pharma: Application for corona treatment drug!
  2. Alzheimer’s disease: New drug suppresses worsening of symptoms!
  3. US FDA: Takeda Pharmaceutical’s Lung Cancer Treatment Approval: Exkivity
  4. Covid-19: Kenya to use Japanese flu drug for treatment
  5. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  6. 💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  7. 💊Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson’s Disease